https://www.selleckchem.com/EGFR(HER).html
001) had lower pulmonary pressures (mean pulmonary artery pressure (mPAP) 31.2 mmHg, standard deviation (SD) ±10.2 versus 32.8 mmHg, SD ±9.7; p less then 0.001) and better outcomes (log-rank p less then 0.001) as compared to the PARAGON-like cohort. However, patients theoretically excluded from the trial (19.2%) were those with most advanced heart failure symptoms (median 6-min walk test 252 m (IQR 165-387); p less then 0.001), highest pulmonary pressures (mPAP 38.2 mmHg, SD ±12.4; p less then 0.001) and worst outcome (log-rank p = 0.037). We
Like
Comment
Share
